GH Research (NASDAQ:GHRS) Trading 0.1% Higher – Here’s What Happened

GH Research PLC (NASDAQ:GHRS)’s stock price traded up 0.1% on Friday . The company traded as high as $9.73 and last traded at $8.98. 44,624 shares changed hands during trading, a decline of 44% from the average session volume of 79,020 shares. The stock had previously closed at $8.97.

Wall Street Analysts Forecast Growth

GHRS has been the subject of several recent analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th.

GH Research Price Performance

The firm has a market cap of $452.66 million, a PE ratio of -13.40 and a beta of 0.74. The business has a 50-day moving average price of $7.75 and a two-hundred day moving average price of $10.38.

GH Research (NASDAQ:GHRS) last announced its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Equities analysts expect that GH Research PLC will post -0.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP raised its stake in GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,310,563 shares of the company’s stock after acquiring an additional 1,471,946 shares during the quarter. GH Research makes up 9.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 6th biggest holding. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 as of its most recent filing with the Securities & Exchange Commission. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).